Anti-sRAGE autoimmunity in obesity: Downturn after bariatric surgery is independent of previous diabetic status

• Published in: Diabetes & metabolism 2014-11, Vol.40 (5), p.356-362
• Main Authors: Lorenzi, R, Pattou, F, Beuscart, J.-B, Grossin, N, Lambert, M, Fontaine, P, Caiazzo, R, Pigeyre, M, Patrice, A, Daroux, M, Boulanger, E, Dubucquoi, S
• Format: Article
• Language: English
• Subjects: Adult; Anti-sRAGE; Autoantibodies - blood; Bariatric surgery; Biological and medical sciences; Biomarker; Biomarkers - blood; Blood Glucose - metabolism; Cardiovascular Diseases - immunology; Cardiovascular Diseases - prevention & control; Diabetes; Diabetes. Impaired glucose tolerance; Diabetic Angiopathies - immunology; Diabetic Angiopathies - prevention & control; Down-Regulation; Endocrine pancreas. Apud cells (diseases); Endocrinology & Metabolism; Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Follow-Up Studies; Gastric Bypass; Humans; Inflammation - immunology; Insulin Resistance - immunology; Internal Medicine; Lipoproteins, HDL - metabolism; Male; Medical sciences; Metabolic diseases; Obesity; Obesity, Morbid - immunology; Obesity, Morbid - surgery; Receptor for Advanced Glycation End Products; Receptors, Immunologic - blood; Receptors, Immunologic - immunology; Weight Loss - immunology
• ISSN: 1262-3636; 1878-1780
• DOI: 10.1016/j.diabet.2014.04.008

Abstract Aim Morbid obesity increases the risk of cardiovascular disease (CVD). The receptor for advanced glycation end-products (RAGE) is implicated in proinflammatory processes that underlie CVD. Its soluble form (sRAGE) has been proposed as a vascular biomarker. Recently, anti-sRAGE autoantibodies were described and found to be increased in diseases where RAGE is overexpressed. This study aimed to investigate serum levels of anti-sRAGE autoantibodies in morbidly obese patients. Methods After exclusion based on specific criteria, 150 subjects (50 normoglycemics, 50 glucose-intolerants and 50 diabetics) were randomly recruited from a cohort of 750 obese patients (ABOS). Serum sRAGE and anti-sRAGE autoantibodies were measured before bariatric surgery. Sixty-nine patients were followed for up to 1 year after gastric bypass, and their levels of sRAGE and anti-sRAGE autoantibodies measured. The control group consisted of healthy blood donors. Results Compared with controls, baseline levels of sRAGE and anti-sRAGE autoantibodies were significantly higher in all obese patients independently of glucose regulation ( P < 0.001). At 1 year after gastric bypass, sRAGE and anti-sRAGE were decreased ( P < 0.001). The decrease in anti-sRAGE autoantibodies was correlated with an increase in high-density lipoprotein (HDL; P = 0.02). Conclusion Independently of previous diabetic status, morbid obesity increases sRAGE and anti-sRAGE levels. Weight loss after gastric bypass is followed by a decrease in both titres. The decrease in anti-sRAGE correlates with an increase in HDL.